A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
← catalyst calendarNCT07187115 · readout ≤ 712 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
699estimated
Sites
15
Countries
Belgium, Hong Kong, Spain +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-07 | actual | When the study began enrolling |
| Primary completion | Jul 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Atrial Fibrillation (AF)
- Persistant Atrial Fibrillation
Interventions
- Device: FARAPOINT Pulsed Field Ablation System
- Device: OptiMap System (non-ablative) — also filed as Ablamap System
- Device: FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System
Primary outcomes
what the primary-completion date above is the date OFPrimary Safety Endpoint
measured 60 Days
Primary Effectiveness Endpoint
measured 365 Days
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed